Hypothalamic Arcuate Nucleus Mediates the Sympathetic and Arterial Pressure Responses to Leptin
Abstract
Leptin is an adipocyte-derived hormone that plays an important role in the regulation of energy homeostasis through its action in the central nervous system. Leptin decreases body weight by promoting satiety and increasing thermogenesis via increasing sympathetic nerve activity (SNA) to brown adipose tissue. Leptin also increases renal SNA and arterial pressure. The arcuate nucleus is considered as a major nucleus for leptin action on energy homeostasis. We tested whether leptin action in the arcuate nucleus simultaneously activates SNA to brown adipose tissue and the kidney. The sympathetic and cardiovascular responses to intra-arcuate injection of leptin were compared with those evoked by intracerebroventricular administration of leptin in rat. Intracerebroventricular administration of leptin (10 μg) caused a significant increase in SNA to brown adipose tissue and the kidney. Intracerebroventricular leptin also increased mean arterial pressure. Direct injection of leptin (500 ng) into the arcuate nucleus increased both brown adipose tissue (254±49%; P<0.001 versus vehicle) and renal SNA (111±31%; P<0.001 versus vehicle). Microinjection of leptin into the arcuate nucleus also produced a substantial increase in mean arterial pressure (from 82±3 to 100±7 mm Hg; P=0.02). These data demonstrate that leptin action in the arcuate nucleus of the hypothalamus is important for the control of sympathetic outflow to both brown adipose tissue and the kidney. These results also suggest that the cardiovascular effects of leptin might be evoked by the action of this hormone in the arcuate nucleus of the hypothalamus.
The adipocyte-derived hormone leptin plays a critical role in the regulation of energy homeostasis.1 Leptin action in the central nervous system decreases body weight by suppressing appetite and increasing energy expenditure. Consistent with its effects on energy expenditure, leptin increases sympathetic nerve activity (SNA) to the thermogenic brown adipose tissue (BAT),2,3 but it also causes sympathoactivation to the kidney, adrenal gland, and hindlimb.3,4 Activation of the autonomic function by leptin has implications for the cardiovascular system. Indeed, systemic, as well as central, administration of leptin increased arterial pressure in the rat.5,6 Transgenic overexpression of leptin in mice also results in higher baseline arterial pressure.7 In contrast, absence of leptin, as in the ob/ob mice, is associated with lower arterial pressure.8
Adrenergic blockade reversed the increase in arterial pressure induced by leptin demonstrating the importance of the sympathetic nervous system in the arterial pressure response to leptin.9 Renal sympathoactivation to leptin seems to play a pivotal role in the increase in arterial pressure induced by this hormone. Indeed, preservation of leptin action on renal SNA, such as in the diet-induced obese mice, is associated with hypertension and a preserved arterial pressure response to leptin.10 In contrast, loss of leptin’s ability to increase renal SNA, such as in the melanocortin-4 receptor knockout mice, is associated with normal baseline arterial pressure and lack of arterial pressure increase after leptin treatment.11–13
The hypothalamus is recognized as an important site of leptin action in the central nervous system.14 The long form of the leptin receptor, which appears to mediate most of the biological effects of leptin, is expressed in several hypothalamic nuclei with higher expression in the arcuate nucleus (ARC).15 Within the ARC, the long form of the leptin receptor is expressed in ≥2 classes of neurons that are critical for the regulation of energy homeostasis: the anorexigenic neurons that express proopiomelanortin peptide and the orexigenic neurons expressing neuropeptide Y and agouti-related peptide.14,15
The observation that ARC-specific gene transfer of the long form of the leptin receptor in rats16 or mice17 lacking functional leptin receptors results in an amelioration of the obesity phenotype demonstrates the importance of leptin signaling in this nucleus for energy homeostasis. Moreover, local injection of leptin into the ARC decreases food intake and body weight in a dose-dependent manner.18 Conversely, lesions of the ARC blunt the feeding- and weight-reducing actions of leptin.19,20 The thermogenic SNA response to leptin was also blocked after the ARC was destroyed.21 Furthermore, direct administration of leptin into the ARC increased lumbar SNA in rats.22 Together, these data suggest that the sympathetic effects of leptin may emanate from this nucleus.
However, to our knowledge, the role of ARC in the renal SNA response to leptin has not been investigated. Therefore, in the present study, we assessed in rats the effects of injecting leptin directly into the ARC on SNA that subserve thermogenic BAT and cardiovascular (kidney) tissues. The changes in arterial pressure and heart rate were recorded simultaneously with SNA. The sympathetic and hemodynamic changes induced by intra-ARC leptin were compared with those evoked by intracerebroventricular (ICV) administration of this hormone.
Methods
Animals
Male Sprague–Dawley rats (Harlan Sprague–Dawley) were used. All of the rats (300 to 350 g) were housed in a temperature-controlled room with a 12:12-hour light–dark cycle. Standard laboratory rat chow and tap water were provided ad libitum. The University of Iowa Animal Research Committee approved all of the procedures. All of the studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Cannulation
Rats were anesthetized by intraperitoneal injection of ketamine (91 mg/kg) and xylazine (9.1 mg/kg) and placed in a stereotactic frame (David Kopf Instruments). The skull was exposed by an incision and leveled between lambda and bregma. ICV cannulation of the third ventricle was performed as described previously.23 The ARC was cannulated unilaterally using a 25-gauge cannula, which was implanted with a 10o angle with the following coordinates relative to bregma: −3.6 mm anteroposterior, +2 mm lateral from the midline, and −8.6 mm dorsoventral from cortex. Each cannula was fixed in place using dental cement, and rats were kept in individual cages postoperatively. Rats were allowed ≥1 week of recovery before experimentation. The position of the cannulae was verified at the end of each experiment as described below.
Sympathetic Nerve Recordings
Simultaneous multifiber recording of SNA was obtained, in anesthetized (ketamine/xylazine mixture, IP) rats, from 2 nerves subserving different beds: BAT and kidney. The left kidney was exposed retroperitoneally through a flank incision. Using a dissecting microscope, a renal nerve was carefully dissected free and placed on a bipolar 36-gauge platinum-iridium electrode (Kwik-Cast, WPI). When optimum recording of SNA was obtained, the electrode was covered with silicone gel (World Precision Instruments, Inc). To record BAT SNA, the BAT was exposed through a nape incision. A nerve fiber innervating BAT was identified, placed on the bipolar platinum–iridium electrode, and secured with silicone gel.
Each electrode was attached to a high-impedance probe (HIP-511, Grass Instruments), and the nerve signal was amplified 105 times with a Grass P5 AC preamplifier. After amplification, the nerve signal was filtered at a 100- and 1000-Hz cutoff with a nerve traffic analysis system (model 706C, University of Iowa Bioengineering). The nerve signal was then routed to an oscilloscope (model 54501A, Hewlett-Packard) for monitoring the quality of the sympathetic nerve recording and to a resetting voltage integrator (model B600c, University of Iowa Bioengineering).
Experimental Protocol
Rats were anesthetized using intraperitoneal ketamine (91 mg/kg) and xylazine (9.1 mg/kg) and instrumented for SNA recordings as described above. Hemodynamic parameters (arterial pressure and heart rate) were monitored through a pressure transducer connected to the catheter inserted in the femoral artery using a pressure transducer connected to a computer. Anesthesia was maintained with α-chloralose (50 mg/kg per hour) via a catheter inserted in the femoral vein. The trachea was cannulated, and each rat was allowed to breathe spontaneously oxygen-enriched air. Rectal temperature was maintained at 37.5°C using a temperature-controlled surgical table and a lamp.
After surgery, rats were allowed to stabilize for 15 to 20 minutes. Baseline SNA for each bed, arterial pressure, and heart rate were then collected on 2 occasions during a 10-minute control period and averaged to obtain a single value for this control period. Each rat then received 1 injection of leptin ICV (10 μg in 4 μL) or unilaterally into the ARC (500 ng in 200 nL) or vehicle (saline, 4 μL ICV or 200 nL intra-ARC); there were 7 rats in each group. After treatment, arterial pressure, heart rate, and SNA measurements were made every 15 minutes for 6 hours.
At the end of the study, the injector was retracted and filled with Evans blue solution and the dye injected ICV (4 μL) or into the ARC (200 nL) to verify the injection site. The animals were euthanized with a lethal dose of ketamine/xylazine and the brain removed. The ICV cannulation was considered successful when the dye was present in the third ventricle. To verify the ARC cannulation, coronal sections (50 μm) were cut with a freezing Microm cryostat. The slices were mounted on slides and the location of the dye verified under microscope. The atlas of Paxinos and Watson24 was used to map the labeled microinjection site. Only animals that showed ARC-specific location of the injections (dye) were included in the present study. Seven rats, including 2 treated with leptin, were excluded from the studies for improper ARC cannulation.
Data Analysis
To ensure that electrical noise was excluded in the assessment of sympathetic outflow, each SNA recording was corrected for postmortem background activity. Because of the animal-to-animal variability in baseline SNA, the data for SNA are expressed as a percentage change from baseline. Results are presented as mean±SEM. Data were analyzed using unpaired t test or repeated-measures ANOVA followed by Newman–Keuls posthoc test. A value of P<0.05 was considered significant.
Results
Effects of ICV Administration of Leptin
ICV administration of leptin caused a significant increase in sympathetic nerve activities and arterial pressure. As shown in Figure 1A, thermogenic BAT SNA response to leptin was robust (increasing from a baseline of 25±3 to 84±9 spikes per second in hour 6 after leptin treatment; P=0.0001). Renal sympathoactivation to ICV leptin was less marked compared with the BAT SNA response (Figure 1B). Renal SNA increased from a baseline of 46±7 to 87±19 spikes per second (P=0.02) in hour 6 after leptin treatment.
ICV administration of leptin raised mean arterial pressure from a baseline of 85±4 to 103±8 mm Hg (P=0.03). The effect of ICV leptin on mean arterial pressure was significantly greater than the effect of ICV vehicle (Figure 2A). This elevation in mean arterial pressure after ICV leptin resulted from an increase in systolic (22±6 mm Hg; P=0.02 versus vehicle) and diastolic (11±5 mm Hg; P=0.04 versus vehicle) arterial pressure.
Although heart rate tended to increase after leptin treatment, this was not different from the effect of vehicle treatment (Figure 2B). ICV administration of vehicle caused no significant change in SNA or arterial pressure.
Sympathetic Nerve Responses to Intra-ARC Administration of Leptin
Administration of leptin directly into the ARC increased regional SNA (Figures 3 and 4). Intra-ARC leptin caused a robust BAT sympathoactivation (Figure 4A). The increase in BAT SNA after leptin treatment was slow and reaches a maximum of 254±49% in hour 6 of treatment, increasing from 18±2 to 65±12 spikes per second (P=0.0006). As shown in Figure 4B, renal SNA was also responsive to microinjection of leptin into the ARC. As with the ICV injection, renal sympathoactivation to intra-ARC leptin was less pronounced, compared with the BAT SNA response, with a maximum increase of 111±31% after 6 hours of treatment, increasing from 57±7 to 115±15 spikes per second (P=0.001). Intra-ARC administration of vehicle did not alter BAT or renal SNA (Figure 4).
Cardiovascular Responses to Intra-ARC Administration of Leptin
Arterial pressure was also responsive to the microinjection of leptin into the ARC (Figures 3 and 5A). Mean arterial pressure increased from a baseline of 82±3 to 100±7 mm Hg in hour 6 after leptin treatment (P=0.02). The rise in mean arterial pressure caused by intra-ARC leptin was much greater than the effect of vehicle treatment (Figure 5A). The increased mean arterial pressure after microinjection of leptin into the ARC reflected an elevation of both systolic (18±6 mm Hg; P=0.03 versus vehicle) and diastolic (11±5 mm Hg; P=0.04 versus vehicle) arterial pressure.
As with the ICV injection, intra-ARC treatments increased heart rate. However, this effect was not significantly different between the leptin and control groups (Figure 5B).
Discussion
In the present study, we investigated the sympathetic and cardiovascular effects of leptin signaling in the ARC of the hypothalamus. The main finding is that leptin action in the ARC increases sympathetic nerve outflow to thermogenic BAT, as well as the kidney. Furthermore, intra-ARC administration of leptin increased arterial pressure. The sympathetic and cardiovascular responses to intra-ARC leptin mimic those induced by ICV administration of this hormone. These data suggest that the ARC is an important site for the sympathetic and cardiovascular effects of leptin.
Early studies have demonstrated the importance of the ARC in transducing the leptin signaling into physiological responses. Indeed, local injection of leptin into the ARC caused a dose-dependent reduction in food intake and body weight.18 Conversely, lesioning the ARC blocks the appetite- and weight-reducing actions of leptin.19,20 Our finding of BAT sympathoactivation to intra-ARC leptin is in agreement with the previous finding showing that lesioning the ARC blunted the BAT sympathoactivation to systemic administration of leptin.21 Together, these data demonstrate that the ARC is a major site for the regulation of thermogenic sympathetic outflow by leptin.
The increase in SNA to tissues other than the BAT after microinjection of leptin into the ARC suggests that leptin signaling in this nucleus is also important for the control of nonthermogenic sympathetic tone. Indeed, microinjection of leptin into the ARC has been shown to increase lumbar SNA in rats.22 Furthermore, our present data demonstrate that renal SNA is also activated after local injection of leptin into this nucleus. Of importance, we found that intra-ARC leptin increased arterial pressure, which was comparable to the effect induced by ICV administration of this hormone. These results suggest that the cardiovascular effects of leptin might be evoked by the action of leptin in the ARC.
The anatomic aspects of the neural connections between the ARC and BAT, as well as the kidneys, have been characterized previously using viral retrograde tracing techniques. Indeed, after injection of the pseudorabies virus into the BAT25,26 or kidneys,22,27 infected cells were found in several brain regions, including the ARC. Furthermore, Oldfield et al28 have shown that the infected neurons in the ARC, after the viral inoculation of BAT, express proopiomelanortin and leptin receptors. Together these studies provide a neuroanatomical basis for the control of BAT and renal SNA by leptin action in the ARC. The difference in the magnitude of BAT versus renal sympathoactivation in response to leptin is consistent with the concept that sympathetic outflow to thermogenic and cardiovascular effectors is differentially regulated.29
Although in the present study the effect of microinjecting leptin into the ARC was compared with the effect of ICV administration of this hormone, the sympathetic and cardiovascular effects of activating the leptin receptor in other hypothalamic nuclei were not investigated. Previous studies have reported differential sympathetic and cardiovascular responses after leptin administration into the hypothalamic nuclei other than the ARC in rats. For instance, Marsh et al30 have reported that injection of leptin into the ventromedial hypothalamic nucleus increased renal SNA and arterial pressure, whereas its injection into the dorsomedial part of the hypothalamus increased only arterial pressure. Reports on the cardiovascular effects of leptin action in the paraventricular nucleus are controversial. Indeed, microinjection of leptin into this nucleus was found to cause no change in arterial pressure or renal SNA,30 to increase lumbar SNA but not arterial pressure,22 or to increase arterial pressure and sympathetic vasomotor tone.31 Several factors may account for such discrepancies in the reported sympathetic and cardiovascular responses induced by microinjection of leptin into the paraventricular nucleus including whether the injections were unilateral or bilateral, the amount of leptin injected, and differences in the exact location within the nucleus of the site of the injection.
In contrast to our findings, Satoh et al32 have shown that microinjection of leptin into the ARC caused no significant change in plasma catecholamines in rats. A leptin-induced increase in catecholamine secretion was found to be caused by the action of leptin in the ventromedial hypothalamus. It should be stressed, however, that plasma levels of catecholamine depend on several processes, including secretion, tissue clearance, and reuptake.33 Therefore, the sensitivity of plasma catecholamine in detecting changes in sympathetic activity is limited.
A major strength of the present study consists in the combination of site-specific injection of leptin into the ARC with simultaneous recording of hemodynamic parameters and SNA to 2 different beds. There are also limitations that need to be addressed. First, we used a dye to ascertain the specificity of the microinjection to the ARC. The reliability of the dye distribution as an indicator of leptin diffusion is not established. Nonetheless, this approach is commonly used to ensure the specificity of the microinjections in the brain.34,35 Second, the experiments were performed in the presence of anesthesia, which may have influenced the cardiovascular and sympathetic responses. For instance, a significant increase in heart rate was observed after ICV and intra-ARC treatments. The fact that bradycardia was evoked by both leptin and vehicle treatments suggest that it may be because of anesthesia. The increase in heart rate did not seem, however, to interfere with the arterial pressure and sympathetic nerve responses to leptin, because the bradycardia occurring in the vehicle-treated rats did not alter the baseline arterial pressure and sympathetic nerve activities. Furthermore, in a previous study we found that presence of anesthesia does not affect the sympathetic responses to different stimuli, including baroreflex activation and hemorrhage.36 Third, we have assessed the short-term sympathetic and cardiovascular responses to leptin. Whether similar responses will be obtained with chronic administration of leptin remains to be determined. Fourth, the downstream mechanisms mediating the SNA and arterial pressure responses to leptin action in the ARC were not examined. We have shown previously the pivotal role of phosphoinositol 3-kinase in the renal SNA response to leptin.37 Microinjection of phosphoinositol 3-kinase inhibitors into the ARC before leptin should reveal whether this signaling pathway in the ARC mediates the sympathetic and cardiovascular responses to leptin.
Perspectives
Obesity is known to be associated with leptin resistance. Studies of 2 animal models of obesity (agouti and diet-induced obese mice) indicate that leptin resistance might not be uniform. In these models, leptin resistance appears to be selectively restricted to the metabolic (feeding- and weight-reducing) actions of leptin, whereas the cardiovascular sympathoexcitatory effects of leptin are preserved.10 Interestingly, the preservation of the regional SNA responses to leptin are not homogeneous but are instead specific to the kidney. Indeed, although renal sympathoactivation to leptin was preserved, the BAT and lumbar SNA responses to leptin were significantly attenuated in obese mice.10 This selectivity in leptin resistance in parallel with the hyperleptinemia that is commonly present in obesity might represent the link between the increase in fat mass and hypertension. However, the processes underlying the selectivity in leptin resistance remain unknown. Future studies are required to understand the mechanisms, within the ARC, that account for the differential resistance to leptin of the regional SNA that is associated with obesity.
Acknowledgments
We thank Drs Allyn L. Mark and Curt D. Sigmund for the critical reading of the article and helpful comments. We also thank Paul Casella for English-language editing and Vickie L. Akers for secretarial assistance.
Source of Funding
K.R. is supported by a Scientist Development Grant from the American Heart Association National Center (grant 0530274N).
Disclosures
None.
References
1.
Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998; 395: 763–770.
2.
Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature. 1996; 380: 677.
3.
Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997; 100: 270–278.
4.
Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997; 46: 2040–2043.
5.
Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension. 1998; 31: 409–414.
6.
Correia ML, Morgan DA, Sivitz WI, Mark AL, Haynes WG. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension. 2001; 37: 936–942.
7.
Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105: 1243–1252.
8.
Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens. 1999; 17: 1949–1953.
9.
Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002; 39: 496–501.
10.
Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes. 2005; 54: 2012–2018.
11.
Rahmouni K, Haynes WG, Morgan DA, Mark AL. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosci. 2003; 23: 5998–6004.
12.
Tallam LS, Stec DE, Willis MA, da Silva AA, Hall JE. Melanocortin-4 receptor-deficient mice are not hypertensive or salt-sensitive despite obesity, hyperinsulinemia, and hyperleptinemia. Hypertension. 2005; 46: 326–332.
13.
Tallam LS, da Silva AA, Hall JE. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin. Hypertension. 2006; 48: 58–64.
14.
Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000; 404: 661–671.
15.
Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999; 22: 221–232.
16.
Morton GJ, Niswender KD, Rhodes CJ, Myers MG Jr, Blevins JE, Baskin DG, Schwartz MW. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity phenotype of Koletsky (fa(k)/fa(k)) rats. Endocrinology. 2003; 144: 2016–2024.
17.
Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang V, Liu SM, Ludwig T, Chua SC Jr, Lowell BB, Elmquist JK. The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 2005; 1: 63–72.
18.
Satoh N, Ogawa Y, Katsuura G, Hayase M, Tsuji T, Imagawa K, Yoshimasa Y, Nishi S, Hosoda K, Nakao K. The arcuate nucleus as a primary site of satiety effect of leptin in rats. Neurosci Letters. 1997; 224: 149–152.
19.
Dawson R, Pelleymounter MA, Millard WJ, Liu S, Eppler B. Attenuation of leptin-mediated effects by monosodium glutamate-induced arcuate nucleus damage. Am J Physiol Endocrinol Metab. 1997; 36: E202–E206.
20.
Tang-Christensen M, Holst JJ, Hartmann B, Vrang N. The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. Neuroreport. 1999; 10: 1183–1187.
21.
Haynes WG. Interaction between leptin and sympathetic nervous system in hypertension. Curr Hypertens Rep. 2000; 2: 311–318.
22.
Montanaro MS, Allen AM, Oldfield BJ. Structural and functional evidence supporting a role for leptin in central neural pathways influencing blood pressure in rats. Exp Physiol. 2005; 90: 689–696.
23.
Rahmouni K, Morgan DA, Morgan GM, Liu XB, Sigmund CD, Mark AL, Haynes WG. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest. 2004; 114: 652–658.
24.
Paxinos G, Watson C. The Rat Brain in Stereortaxic Coordinates. New York, NY: Academic Press; 2005.
25.
Cano G, Passerin AM, Schiltz JC, Card JP, Morrison SF, Sved AF. Anatomical substrates for the central control of sympathetic outflow to interscapular adipose tissue during cold exposure. J Comp Neurol. 2003; 460: 303–326.
26.
Bamshad M, Song CK, Bartness TJ. CNS origins of the sympathetic nervous system outflow to brown adipose tissue. Am J Physiol-Regul Integr Comp Physiol. 1999; 276: R1569–R1578.
27.
Cano G, Card JP, Sved AF. Dual viral transneuronal tracing of central autonomic circuits involved in the innervation of the two kidneys in rat. J Comp Neurol. 2004; 471: 462–481.
28.
Oldfield BJ, Giles ME, Watson A, Anderson C, Colvill LM, McKinley MJ. The neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown adipose tissue in the rat. Neuroscience. 2002; 110: 515–526.
29.
Morrison SF. Differential control of sympathetic outflow. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R683–R698.
30.
Marsh AJ, Fontes MA, Killinger S, Pawlak DB, Polson JW, Dampney RA. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension. 2003; 42: 488–493.
31.
Shih CD, Au LC, Chan JYH. Differential role of leptin receptors at the hypothalamic paraventricular nucleus in tonic regulation of food intake and cardiovascular functions. J Biol Sci. 2003; 10: 367–378.
32.
Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki H, Hosoda K, Yoshimasa Y, Nakao K. Sympathetic activation of leptin via the ventromedial hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes. 1999; 48: 1787–1793.
33.
Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999; 17: 719–734.
34.
Lohman RJ, Liu LG, Morris M, O’Brien TJ. Validation of a method for localised microinjection of drugs into thalamic subregions in rats for epilepsy pharmacological studies. J Neurosci Methods. 2005; 146: 191–197.
35.
Chen QH, Haywood JR, Toney GM. Sympathoexcitation by PVN-injected bicuculline requires activation of excitatory amino acid receptors. Hypertension. 2003; 42: 725–731.
36.
Morgan DA, Thoren P, Staudt SM, Mark AL. Differential effects of anesthesia on heart rate (HR), renal (RSNA), and lumbar sympathetic nerve activity (LSNA) in the rat. FASEB J. 1988; 2: A1690–A1690.
37.
Rahmouni K, Haynes WG, Morgan DA, Mark AL. Intracellular mechanisms involved in leptin regulation of sympathetic outflow. Hypertension. 2003; 41: 763–767.
Information & Authors
Information
Published In
Copyright
© 2007.
Versions
You are viewing the most recent version of this article.
History
Received: 13 October 2006
Revision received: 1 November 2006
Accepted: 29 November 2006
Published online: 26 December 2006
Published in print: 1 March 2007
Keywords
Subjects
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- The New Challenge of Obesity - Obesity-Associated Nephropathy, Diabetes, Metabolic Syndrome and Obesity, Volume 17, (1957-1971), (2024).https://doi.org/10.2147/DMSO.S433649
- The growing complexity of the control of the hypothalamic pituitary thyroid axis and brown adipose tissue by leptin, , (2024).https://doi.org/10.1016/bs.vh.2024.07.005
- miRNA and leptin signaling in metabolic diseases and at extreme environments , Pharmacology Research & Perspectives, 12, 4, (2024).https://doi.org/10.1002/prp2.1248
- The characteristics of elevated blood pressure in abdominal obesity correspond to primary hypertension: a cross-sectional study, BMC Cardiovascular Disorders, 23, 1, (2023).https://doi.org/10.1186/s12872-023-03150-w
- Cardiovascular Characteristics of Zucker Fatty Diabetes Mellitus Rats, an Animal Model for Obesity and Type 2 Diabetes, International Journal of Molecular Sciences, 23, 8, (4228), (2022).https://doi.org/10.3390/ijms23084228
- Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging, International Journal of Molecular Sciences, 23, 2, (963), (2022).https://doi.org/10.3390/ijms23020963
- Reciprocal signaling between adipose tissue depots and the central nervous system, Frontiers in Cell and Developmental Biology, 10, (2022).https://doi.org/10.3389/fcell.2022.979251
- Protein Tyrosine Phosphatase 1B Deficiency Improves Glucose Homeostasis in Type 1 Diabetes Treated With Leptin, Diabetes, 71, 9, (1902-1914), (2022).https://doi.org/10.2337/db21-0953
- The interactions between adipose tissue secretions and Parkinson's disease: The role of leptin, European Journal of Neuroscience, 55, 3, (873-891), (2022).https://doi.org/10.1111/ejn.15594
- Hypothalamic control of energy expenditure and thermogenesis, Experimental & Molecular Medicine, 54, 4, (358-369), (2022).https://doi.org/10.1038/s12276-022-00741-z
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.